Weshalb die Arrowhead Pharmaceuticals-Aktie
ein B-Rating hat,
erfahren Sie im Performance-Check
vom 18. September 2025 Info.
Rang | Datum | Vorjahr | Schluss | Performance |
---|---|---|---|---|
1 | 2019 | 10,64 | 58,55 | 450,28% |
2 | 2013 | 1,49 | 7,87 | 428,19% |
3 | 2018 | 3,35 | 10,64 | 217,61% |
4 | 2017 | 1,54 | 3,35 | 117,53% |
5 | 2010 | 3,27 | 6,61 | 102,14% |
6 | 2025 | 19,00 | 24,61 | 29,53% |
7 | 2005 | 34,00 | 37,00 | 8,82% |
8 | 2020 | 58,55 | 63,20 | 7,94% |
9 | 2015 | 5,39 | 5,61 | 4,08% |
10 | 2021 | 63,20 | 58,50 | -7,44% |
11 | 2006 | 37,00 | 33,20 | -10,27% |
12 | 2007 | 33,20 | 26,10 | -21,39% |
13 | 2023 | 37,30 | 27,94 | -25,09% |
14 | 2014 | 7,87 | 5,39 | -31,51% |
15 | 2024 | 27,94 | 19,00 | -32,00% |
16 | 2022 | 58,50 | 37,30 | -36,24% |
17 | 2011 | 6,61 | 3,22 | -51,29% |
18 | 2009 | 7,06 | 3,27 | -53,68% |
19 | 2012 | 3,22 | 1,49 | -53,73% |
20 | 2016 | 5,61 | 1,54 | -72,55% |
Rang | Datum | Vorjahr | Schluss | Performance |
---|---|---|---|---|
1 | 2008 | 26,10 | 7,06 | -72,95% |
2 | 2016 | 5,61 | 1,54 | -72,55% |
3 | 2012 | 3,22 | 1,49 | -53,73% |
4 | 2009 | 7,06 | 3,27 | -53,68% |
5 | 2011 | 6,61 | 3,22 | -51,29% |
6 | 2022 | 58,50 | 37,30 | -36,24% |
7 | 2024 | 27,94 | 19,00 | -32,00% |
8 | 2014 | 7,87 | 5,39 | -31,51% |
9 | 2023 | 37,30 | 27,94 | -25,09% |
10 | 2007 | 33,20 | 26,10 | -21,39% |
11 | 2006 | 37,00 | 33,20 | -10,27% |
12 | 2021 | 63,20 | 58,50 | -7,44% |
13 | 2015 | 5,39 | 5,61 | 4,08% |
14 | 2020 | 58,55 | 63,20 | 7,94% |
15 | 2005 | 34,00 | 37,00 | 8,82% |
16 | 2025 | 19,00 | 24,61 | 29,53% |
17 | 2010 | 3,27 | 6,61 | 102,14% |
18 | 2017 | 1,54 | 3,35 | 117,53% |
19 | 2018 | 3,35 | 10,64 | 217,61% |
20 | 2013 | 1,49 | 7,87 | 428,19% |